Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.

Nassa G, Salvati A, Tarallo R, Gigantino V, Alexandrova E, Memoli D, Sellitto A, Rizzo F, Malanga D, Mirante T, Morelli E, Nees M, Åkerfelt M, Kangaspeska S, Nyman TA, Milanesi L, Giurato G, Weisz A.

Sci Adv. 2019 Feb 6;5(2):eaav5590. doi: 10.1126/sciadv.aav5590. eCollection 2019 Feb.

2.

Association of tamoxifen resistance and lipid reprogramming in breast cancer.

Hultsch S, Kankainen M, Paavolainen L, Kovanen RM, Ikonen E, Kangaspeska S, Pietiäinen V, Kallioniemi O.

BMC Cancer. 2018 Aug 24;18(1):850. doi: 10.1186/s12885-018-4757-z.

3.

Consistency in drug response profiling.

Mpindi JP, Yadav B, Östling P, Gautam P, Malani D, Murumägi A, Hirasawa A, Kangaspeska S, Wennerberg K, Kallioniemi O, Aittokallio T.

Nature. 2016 Nov 30;540(7631):E5-E6. doi: 10.1038/nature20171. No abstract available.

PMID:
27905421
4.

Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.

Kangaspeska S, Hultsch S, Jaiswal A, Edgren H, Mpindi JP, Eldfors S, Brück O, Aittokallio T, Kallioniemi O.

BMC Cancer. 2016 Jul 4;16:378. doi: 10.1186/s12885-016-2452-5.

5.

Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.

Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S.

Sci Transl Med. 2014 Mar 26;6(229):229ra41. doi: 10.1126/scitranslmed.3008326.

6.

Reanalysis of RNA-sequencing data reveals several additional fusion genes with multiple isoforms.

Kangaspeska S, Hultsch S, Edgren H, Nicorici D, Murumägi A, Kallioniemi O.

PLoS One. 2012;7(10):e48745. doi: 10.1371/journal.pone.0048745. Epub 2012 Oct 31.

7.

KRAS oncogene rearrangements and gene fusions: unexpected rare encounters in late-stage prostate cancers.

Edgren H, Kangaspeska S, Kallioniemi O.

Cancer Discov. 2011 Jun;1(1):12-3. doi: 10.1158/2159-8274.CD-11-0045. Epub 2011 Jun 1.

8.

Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.

Östling P, Leivonen SK, Aakula A, Kohonen P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici D, Bjartell A, Ceder Y, Perälä M, Kallioniemi O.

Cancer Res. 2011 Mar 1;71(5):1956-67. doi: 10.1158/0008-5472.CAN-10-2421. Epub 2011 Feb 22.

9.

Identification of fusion genes in breast cancer by paired-end RNA-sequencing.

Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, Rye IH, Nyberg S, Wolf M, Borresen-Dale AL, Kallioniemi O.

Genome Biol. 2011;12(1):R6. doi: 10.1186/gb-2011-12-1-r6. Epub 2011 Jan 19.

10.

E2-mediated cathepsin D (CTSD) activation involves looping of distal enhancer elements.

Bretschneider N, Kangaspeska S, Seifert M, Reid G, Gannon F, Denger S.

Mol Oncol. 2008 Aug;2(2):182-90. doi: 10.1016/j.molonc.2008.05.004. Epub 2008 May 29.

11.

Transient cyclical methylation of promoter DNA.

Kangaspeska S, Stride B, Métivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, Benes V, Gannon F, Reid G.

Nature. 2008 Mar 6;452(7183):112-5. doi: 10.1038/nature06640.

PMID:
18322535
12.

Interfering with the dynamics of estrogen receptor-regulated transcription.

Johnsen SA, Kangaspeska S, Reid G, Gannon F.

Ernst Schering Found Symp Proc. 2006;(1):1-12. Review.

PMID:
17824168

Supplemental Content

Loading ...
Support Center